Instead of a traditional IPO, Candid Therapeutics secured a NASDAQ listing and a massive capital infusion by merging with RallyBio. This reverse merger, coupled with a concurrent private investment, provides nearly $700 million in cash to fund operations through 2030, demonstrating a powerful alternative financing path to public markets.

The path to a successful biotech IPO has changed. The traditional VC-to-public handoff is obsolete. Now, securing pre-IPO investment from public market funds in a 'crossover' round is critical to ensure the offering is oversubscribed and well-received from the start.

Reverse mergers are no longer a 'back door' listing method. Their acceptance by high-quality companies is driven by the concurrent PIPE financing, which recapitalizes the company and brings in a supportive, institutional shareholder base, mitigating the risk of inheriting a mismatched investor group.

Biotech firms are increasingly using reverse mergers paired with substantial PIPE financings ($200M+) as an alternative path to the public markets. This "IPO-esque" strategy offers speed and efficiency but may trade off the broader investor exposure gained through a traditional, lengthy roadshow process.

When traditional venture funding dried up for Madrigal Pharmaceuticals, they found an unconventional path to capital and a public listing. They pursued a reverse merger with Cinta, a public company that had recently failed a Phase 3 trial and was seeking an exit. This "bake off" victory secured Madrigal $41 million.

Biotech companies are increasingly favoring reverse mergers over traditional IPOs. The process allows for confidential diligence with select funds, is faster, and sidesteps market volatility like election uncertainty. The previous stigma is fading as the quality of investor syndicates remains high.

Remix Therapeutics is going public by merging with an existing public company, Passage Bio, and raising a concurrent $100M financing. This reverse merger strategy provides a faster and potentially less volatile route to the stock exchange compared to a traditional IPO, allowing them to quickly capitalize on positive clinical momentum.

Once viewed negatively as a "breach of birth," reverse mergers are now a credible and efficient path to the public markets for biotech companies. They can compress timelines and save money, rivaling traditional IPOs in legitimacy.

The 'NewCo' model, which creates a Western company around in-licensed Asian assets, is now leveraging reverse mergers for a fast track to public markets. Slate Medicines' deal with Fulcrum Therapeutics exemplifies this trend, following similar moves by companies like Yarrow and Serapha, shortening the path from inception to public listing.